Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Omid HamidKarl D LewisAmy WeiseMeredith A McKeanKyriakos P PapadopoulosJohn CrownTae Min KimDae Ho LeeSajeve S ThomasJanice MehnertJohn KaczmarNehal J LakhaniKevin B KimMark Ross MiddletonGuilherme RabinowitsAlexander I SpiraMelinda YushakInderjit MehmiFang FangShuquan ChenJayakumar ManiVladimir JankovicFang WangNathalie FiaschiLaura BrennanAnne J PaccalySheila MasindeMark SalvatiMatthew G FuryGlenn S KroogIsrael LowyGiuseppe GulloPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
The current results show a promising benefit-risk profile of fianlimab/cemiplimab combination for patients with advanced melanoma, including those with previous anti-PD-1 therapy in the adjuvant, but not advanced, setting.